USFDA approves Alembic Pharma five products in over a month

Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringe, final approval, of Hoffmann LA Roche Inc with brand name, Valium (Diazepam) Injection, is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.

Selexipag Tablets 1,000 mcg and 1,200 mcg, tentative approval, of Actelion Pharmaceuticals Inc. with brand name, Uptravi, is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalisation for PAH.

Binimetinib, tentative approval, of Array Biopharm with brand name, Mektovi, is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Tretinoin Cream USP, 0.1%, final approval, of Bausch Health US, LLC., USA with brand name, Retin-A, is indicated for topical application in the treatment of acne vulgaris.

Clindamycin Phosphate Topical Gel USP 1%, final approval, of Pharmacia & Upjohn with brand name, Cleocin T, is indicated in the treatment of acne vulgaris.

Alembic has a cumulative total of 201 ANDA approvals (173 final approvals and 28 tentative approvals) from USFDA.

Headquartered in India, Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. It is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.